On March 27, 2019, Emerald Health Therapeutics, Inc. entered into an equity distribution agreement with GMP Securities L.P., as sole agent, pursuant to which Emerald may sell common shares of the Company for aggregate gross proceeds of up to $39 million. Sales of Common Shares will be made through the agent as “at-the-market distributions” on the TSX Venture Exchange or any other recognized marketplace upon which the common shares are listed or quoted or where the common shares are traded in Canada. The offering will be made by way of a prospectus supplement dated March 27, 2019 to Emerald’s short form base shelf prospectus dated March 13, 2019. The prospectus supplement relating to the offering has been filed with the securities commissions in each of the provinces of Canada and the United States Securities and Exchange Commission. The Company expects to use the net proceeds of the offering, if any, to fund a portion of the costs for the completion of its capital projects, for research and development, working capital and general corporate purposes. In connection with the offering Bennett Jones LLP acted as legal counsel to the Company with a team consisting of James Beeby, Lisa Kakoske and Tajinder Rathor. Blake, Cassels & Graydon LLP acted as legal counsel to the agent, with a team consisting of Michael Hickey, Tim Phillips and Ted Gotlieb.